Bio-Rad Laboratories (NYSE:BIO) is shown to maintain control over its debt, but some experts have concerns about the speed of the company shares' growth. With their stocks being sold by
Anchor Capital Advisors and Natixis Advisors, shareholders include
First Pacific Advisors, Zurcher Kantonalbank and Allspring Global Investments. Despite some executives increasing their direct ownership, the company suffered a
54% loss over three years. Future estimates place
Bio-Rad's share price at approximately
$358.20. The second quarter financial results for 2024 reveal exceeded earnings predictions, but the projection for Q3 is lower. There's a mixed reaction to Bio-Rad's current financial standing. While they have announced a
$500M share repurchase program, they've also had a net sales drop of 3%. Their stock price plummeted 20% on the announcement of an updated 2024 outlook further causing tensions among investors. News of a rumored
$10 billion Qiagen buyout surfaced but many remain doubtful over its likelihood. Overall, the financial future of
Bio-Rad Laboratories remains uncertain.
Bio-Rad Laboratories Stocks News Analytics from Mon, 13 Feb 2017 08:00:00 GMT to Sun, 08 Sep 2024 14:15:30 GMT -
Rating -2
- Innovation 5
- Information 2
- Rumor -8
